GSK plc【GSK】株式ニュース

個人投資家向けのプロ仕様のツール。

Contact The Gross Law Firm by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)

Contact The Gross Law Firm by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK) PR Newswire NEW...

PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in...

Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact The Gross Law Firm PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK plc Class Action: The Gross Law Firm Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK

GSK plc Class Action: The Gross Law Firm Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead...

GSK Enters Agreement to Acquire IDRx, Inc.

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Monksdream 5月前

GSK up and down but mostly up

has anybody here seen that enzolytics pharm announced that they have a cure for hiv/aids yesterday.

👍️0

MrHankey 2年前

Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

"Requesting copies of the letter and/or all communications from the FDA to GSK requesting the withdrawal of GSK's Blenrep from the market in the US, as widely reported in November 2022."

https://www.fda.gov/media/170006/download

👍️0

Magnum7419 2年前

i am in 100@ 34.56 :)

Post hoc analysis shows that biomarker correlates with response to NY-ESO-1 TCR-T cells in patients with synovial sarcoma https://www.nature.com/articles/s41467-022-32491-x

👍️0

BottomBounce 3年前

$GSK Total Debt is $22.11 Billion // $8.00 should be trading

👍️0

rosemountbomber 3年前

Anyone know how we will calculate our cost basis in Haleon?

👍️0

ruke 3年前

So, why shares aren't realy mooning in pre-market? Isn't that strange?

👍️0

jondoeuk 3年前

Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition https://www.medpagetoday.com/meetingcoverage/asco/99071

👍️0

jondoeuk 3年前

Lete-Cel ASCO data https://www.cgtlive.com/view/lete-cel-exhibits-anti-tumor-activity-long-median-pfs-patients-myxoid-round-cell-liposarcoma

👍️0

jondoeuk 3年前

The company has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses LYEL's Epi-R https://lyell.com/our-platforms

New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''

👍️0

jondoeuk 4年前

They have shared some preclinical data https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165ds1.htm

👍️0

jondoeuk 4年前

Preclinical data from another group: ''Hepatocellular carcinoma (HCC) is responsible for most of primary liver cancer cases and is the sixth most common cancer in the world with a general 5 year survival rate of 18% due to lack of effective therapy. Adoptive T-cell therapy (ACT) with T-cell receptor–engineered T-cell (TCR-T) against HCC-associated antigen a-fetoprotein (AFP), can redirect human T cells to recognize and kill HCC tumor cells.

However, the clinical efficacy of TCR-T therapy is dependent on the proper expansion, in vivo persistence of T cells that is markedly reduced due to exhaustion-associated dysfunction, and activation induced cell death. To improve persistence of TCR-T cells without modifying TCR affinity, we engineered TCR-T cells to overexpress c-Jun, an AP-1 transcription factor associated with T cell development and activation. In this study, we showed that TCR-T cells overexpressing c-Jun have enhanced expansion capacity in culture, improved cytokine production against HepG2 tumor cells without altering their cytotoxic potential.

Interestingly TCR-T cells overexpressing c-Jun showed resistance to activation induced cell death with decreased expression of inhibitory receptors after stimulation with HepG2 tumor cells. Thus, c-Jun overexpression could be a potential therapeutic agent to enhance the anti-tumor efficacy of TCR-T cells against HCC.''

https://virtual.aai.org/aai/2021/virtual-immunology-2021/317351/mohamed.hussein.the.role.of.c-jun.in.enhancing.tcr-t.function.in.treatment.of.html

👍️0

jondoeuk 4年前

Some more info https://lyell.com/our-platforms

👍️0

stillness0007 4年前

GSK V TEVA question. The panel of judges heard the case on Feb 23rd. Am I right to understand, usually a decision is made 3-4 months after that? Cause some are saying by end of 2022, which makes no sense to me.

👍️0

testing4covid 4年前

Achiko AG: The One Ecosystem that Takes a ‘Swiss Cheese’ Approach to COVID-19

Great article on an upcoming testing technology:

https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte

👍️0

whytestocks 4年前

Breaking News: $GSK Investors Wish They Could Vote These 2 Healthcare CEOs Out

One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management. But some investors might ...

Read the whole news GSK - Investors Wish They Could Vote These 2 Healthcare CEOs Out

👍️0

jondoeuk 4年前

Decitabine has been shown to induce cancer-testis antigen expression https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139221

👍️0

jondoeuk 4年前

SITC

Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)

👍️0

jondoeuk 4年前

Going forward, I would like them to transduce half of the CD4+ T-cells with an NY-ESO-1 specific MHC II restricted TCR [1], and the other half to co-express a CD8a. Combining both CD4+ and CD8+ can induce bystander killing of antigen-negative cancer cells [2,3]. Also, some of the CD4+ can show tumoricidal activity by their own means irrespective of MHC II expression [4-7].

Refs:
1 https://www.nejm.org/doi/full/10.1056/nejmoa0800251
2 https://rupress.org/jem/article/207/11/2469/40645/Bystander-killing-of-cancer-requires-the
3 https://www.nature.com/articles/srep14896
4 https://cancerres.aacrjournals.org/content/70/21/8368.long
5 https://rupress.org/jem/article/154/3/952/49262/Eradication-of-disseminated-murine-leukemia-by
6 https://rupress.org/jem/article/207/3/637/40473/Tumor-reactive-CD4-T-cells-develop-cytotoxic
7 https://www.cell.com/immunity/fulltext/S1074-7613(00)80218-6

👍️0

jondoeuk 4年前

Lyell plan to use defined cell populations [1], improve ex vivo expansion [2-4], and a novel co-stim [5].

Refs:
1 https://www.nature.com/articles/leu2015247
2 https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543
3 https://cancerres.aacrjournals.org/content/75/2/296.long
4 https://link.springer.com/article/10.1007%2Fs00262-012-1378-2
5 https://www.nature.com/articles/s41586-019-1805-z

👍️0

jondoeuk 4年前

Hopefully, trials testing these improvements will start early next year https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level

👍️0

jondoeuk 4年前

A new trial testing the NY-ESO-1 TCR-T cell therapy product [1] which either co-expresses a CD8a [2] or dnTGFßRII [2].

Refs:
1 https://clinicaltrials.gov/ct2/show/NCT04526509
2 (Some of the R&D was conducting with ADAP) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research

👍️0

MustBeTheTruth 5年前

Better Development Tools for a New Golden Era of Psychopharmacology

https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/

👍️0

T695 5年前

Calls might sky rocket tomorrow

Trump promises Cincinnati rally that US will end AIDS epidemic and find a cure for childhood cancer 'very shortly'

https://www.businessinsider.com/trump-cincinnati-promises-cure-cancer-and-aids-very-shortly-2019-8

👍️0

BottomBounce 5年前

$GSK Democratic-run House approves its $3 trillion relief measure in vote late Friday https://www.marketwatch.com/story/next-coronavirus-aid-package-expected-to-become-reality-in-june-at-the-earliest-as-house-prepares-to-pass-its-bill-on-friday-2020-05-15?mod=mw_more_headlines

👍️0

BottomBounce 5年前

Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
Collaboration

https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx

👍️0

BottomBounce 5年前

**** BREAKING HIV $GSK <<<< Drug giant GSK today declared a major breakthrough on a new HIV treatment it was trialling in patients that could prevent the spread of the disease. https://www.standard.co.uk/business/drug-giant-gsk-sees-major-breakthrough-on-hiv-treatment-a4442996.html

👍️0

Nebuchadnezzar 5年前

GSK-especially now in current market turmoil $35 looks XTRA tasty

👍️0

BottomBounce 5年前

Sci-B-Vac data is in December. That's the drug beating $GSK's Engerix-B

The infection prevention rate for $VBIV 91.4% for Sci-B-Vac

The infection prevention rate for $GSK 76.5% for Engerix-B

👍️0

BottomBounce 5年前

$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

👍️0

BottomBounce 5年前

$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK ) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent

👍️0

BottomBounce 5年前

$GSK and $VBIV VBI Vaccines teams up with Glaxo on therapeutic cancer vaccine https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent

👍️0

Robbinhood101 5年前

Watch this one go up with Tesaro approval.

👍️0

I Need Money 5年前

Certainly a great LONG term hold. ;)

👍️0

Don'tDrinkTheKoolAid 5年前

YIKES haha nice up tick with a great divvy.

Don'tDrinkTheKoolAid 6年前

Yep 39 now with 5% divvy I don't own it now :(!

👍️0

DewDiligence 6年前

GSK, PFE form consumer-health JV: #msg-145552190.

👍️0

Dhubbard5 6年前

I agree with your theory completely make total sense.

👍️0

debunker1 7年前

Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.

👍️0

Don'tDrinkTheKoolAid 7年前

Buy anything below 36 not much down side risk.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

GSK plc (GSK)

個人投資家向けのプロ仕様のツール。

GSK ニュース

Contact The Gross Law Firm by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)

PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact The Gross Law Firm

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK plc Class Action: The Gross Law Firm Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK

GSK Enters Agreement to Acquire IDRx, Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK 財務

GSK Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

GSK plc (GSK) ニュース

GSK plc (GSK)

個人投資家向けのプロ仕様のツール。

GSK ニュース

Contact The Gross Law Firm by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)

PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact The Gross Law Firm

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK plc Class Action: The Gross Law Firm Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK

GSK Enters Agreement to Acquire IDRx, Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK 財務

GSK Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する